Shenzhen GPO issued the second procurement plan, several questions to be solved

Source: minenet 2016-9-29 after seeking public opinions from the public on the procurement plan of Shenzhen Public Hospital Pharmaceutical Group (the first batch) on September 14, 2016, nearly half a month later, the draft of the second batch of the first part of the procurement plan was published today, organized by Shenzhen public hospital pharmaceutical procurement group“ As mentioned on the official website of Shenzhen quanyao Pharmaceutical Co., Ltd., the deadline for consultation is 18:00 on September 30, 2016 The drugs involved in the procurement are different from the first batch of drugs, mainly including chemical drugs, biological products and basic infusion The procurement plan of Chinese patent medicine will be issued separately "This second procurement plan has several characteristics First, all of them adopt the way of negotiation, the first level is direct negotiation, the third level is shortlisted for negotiation, in the form of face-to-face negotiation or online negotiation; second, the composition of technical bid contains some scoring items which are controversial " Chen Hao, a researcher at the center for drug policy and management, Tongji Medical College, Huazhong University of science and technology, thinks Among them, there are still some questions in the draft in the current discussion In the purchase flow chart, chemical drugs and biological products are mentioned, and a transaction is finally determined In terms of "transaction confirmation" below, it is mentioned that: (1) chemicals and biological products 1 The same bidding group finally determines that the products of one enterprise are transaction varieties, and other shortlisted enterprises are candidate transaction varieties 2 The transaction price of drugs in the third quality level shall not be higher than the lowest transaction price in the first and second quality levels If there is a reverse hanging, the lowest transaction price shall be adjusted Chen Hao said that when it comes to selecting the lowest price of each level in the text, but in the flow chart, it is the final one of the three levels This is very ambiguous The determination of "one" is at the level of supply of the whole drug network, which means that only one product is purchased by the whole drug network and only one hospital is available This approach has achieved volume procurement, but the problem is that if the selected one is from the lowest level, it is possible to achieve the price reduction goal, but it may bring quality and efficacy risks If the selected one is not the lowest level, the price reduction target may not be achieved No matter how to choose, in fact, it has resulted in the disappearance of the opportunity for hospitals to choose multi-level drugs How to deal with the balance between cost control objectives, multi-level drug selection and hierarchical diagnosis and treatment? From the wording of the implementation plan of the second batch of purchase catalogue of quanyao.com, in the purchase process, each manufacturer or business enterprise is required to make a supply quotation to quanyao.com, which means quanyao.com, as a business enterprise, participates in the drug supply system of public medical institutions in Shenzhen, and is the only drug supply institution in fact In a sense, it has become a public hospital and government in Shenzhen To hold the sole trusteeship business for drug use in primary medical institutions This trusteeship business collects supply prices from drug manufacturers, but there is still no clear statement about what price the whole drug network supplies to medical institutions It is still unknown whether or not the whole drug network adopts the addition in the purchase of drug groups and how much the addition rate is In the process of providing drugs to all levels of public hospital system in the city, whether it is a global trusteeship business or a drug group purchasing organization that only provides purchasing services as determined at the beginning of GPO scheme design, does not participate in the operation and distribution, and there is no consensus In terms of the current operation process, it has been deeply involved in the drug business In fact, it is a trusteeship business rather than a pure group procurement service organization From this point of view, it is the same as the pharmacy of Nanjing public hospital hosted by Nanjing Pharmaceutical many years ago It is still unclear how to achieve the harmony of public interest and commercial interest in the procurement of drugs group of the city's public hospitals organized and operated by this pharmaceutical commercial enterprise In the process of drug group purchasing, how to strictly abide by the drug management law and drug quality management standards is the most basic legal requirement for it as a drug handling enterprise According to the procurement plan, it is actually responsible for supplying drugs to public hospitals as a business enterprise, and it must strictly abide by relevant laws and regulations, such as the same trade of goods tickets and corresponding accounts of goods tickets, and establish a storage system that is suitable for the operation and the structure and scale of drug varieties If the provisions of drug law and GSP are violated in the purchase process of drug group, the validity of its existence is in doubt This will shake the foundation of this drug purchase reform Original link: http://www.menu.com.cn/info/201609/201609290931593159_.shtml